Geron Corporation (GERN)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Geron Corporation.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 1.30 $ — 22% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
5 of 10 Solid growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 575.4% passed
- More than 10% revenue growth is expected for the coming year 42.5% passed
- Share count grows by less than 3% a year 20.5% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 78.4% passed
- Gross margin at 40% or higher and without meaningful erosion 97.4% failed
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 108 m net cash passed
- Operating cash flow covers the profits of the last three years -53 m failed
- Return on capital at 15% or higher, or up versus two years ago -11.7% failed
- Insiders hold at least 10% or are net buyers 0.1% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 226.9% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 9
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.02 | -0.02 – -0.02 | 234 | 80.6% | 2 |
| 12/31/2027 | 0.06 | 0.04 – 0.08 | 342 | 400.0% | 2 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.01 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.04 | – | 48 | 206,582.60 | -53.30 | -44 | -44 |
| 2025: Q1 | -0.03 | – | 40 | 12,927.30 | -50.10 | -48 | -48 |
| 2025: Q2 | -0.02 | – | 49 | 5,459.60 | -33.40 | -27 | -28 |
| 2025: Q3 | -0.03 | – | 47 | 67.10 | -39.00 | -14 | -14 |
| 2025: Q4 | -0.05 | – | 48 | 1.00 | -64.90 | -22 | -22 |
| 2026: Q1 | -0.01 | – | 52 | 30.90 | -7.00 | -63 | -63 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 6 | -31 | -30 | -0.19 | -18 | 122 | 130 |
| 2017 | 1 | -29 | -28 | -0.18 | -21 | 104 | 110 |
| 2018 | 1 | -31 | -27 | -0.15 | -21 | 178 | 185 |
| 2019 | 0 | -73 | -64 | -0.33 | -44 | 135 | 166 |
| 2020 | 0 | -77 | -76 | -0.28 | -67 | 211 | 271 |
| 2021 | 1 | -114 | -116 | -0.35 | -96 | 126 | 226 |
| 2022 | 1 | -139 | -142 | -0.37 | -127 | 80 | 191 |
| 2023 | 0 | -194 | -184 | -0.32 | -168 | 248 | 394 |
| 2024 | 77 | -174 | -175 | -0.27 | -219 | 280 | 594 |
| 2025 | 184 | -54 | -86 | -0.13 | -111 | 226 | 571 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
| Employees | 258 |
|---|---|
| Headquarters | Foster City, CA |
| Address | 919 East Hillsdale Boulevard, 94404 Foster City, United States |
| Phone | 650 473 7700 |
| Website | geron.com |
| IPO Date | 30. Jun 1996 |
| ISIN | US3741631036 |
| Stock Split | 1058:1000 on 07/22/2014 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Harout Semerjian | CEO, President & Director | 1970 |
| Michelle J. Robertson | EVP, CFO, Treasurer and Principal Financial & Accounting Officer | 1967 |
| Joseph Emile Eid M.D. | Executive VP of Research & Development and Chief Medical Officer | 1967 |
| Ahmed ElNawawi | Executive VP & Chief Commercial Officer | 1981 |
| Shanthakumar Tyavanagimatt | Senior VP & Chief Technical Officer | – |
| Dawn Schottlandt CFA | Senior Vice President of Investor Relations & Corporate Affairs | – |
| Timothy Williams J.D. | Executive VP, Chief Legal Officer & Corporate Secretary | 1977 |
| Aron Feingold | Vice President of Investor Relations & Corporate Communications | – |
| Shannon T. Odam | Executive VP & Chief People Officer | 1975 |
| Bryan Ridgell | Senior VP of Portfolio & Project Management and Chief of Staff | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.